Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Ophthalmology, L.V. Prasad Eye Institute, Hyderabad, India.
Graefes Arch Clin Exp Ophthalmol. 2020 Jun;258(6):1191-1197. doi: 10.1007/s00417-020-04619-6. Epub 2020 Mar 13.
To assess whether treatment of chronic central serous chorioretinopathy (cCSC) with photodynamic therapy (PDT) and high-density subthreshold micropulse laser (HSML) results in choroidal vascularity index (CVI) changes that may account for the treatment effect.
Patients with cCSC were prospectively included and analyzed. Patients received either half-dose PDT or HSML treatment. CVI of the affected and unaffected eye was obtained before treatment, 6 to 8 weeks after treatment, and 7 to 8 months after treatment.
At baseline, 29 eyes (29 patients) were included both in the PDT and in the HSML group. The mean (± standard deviation) CVI change in the HSML group between before PDT and 6 to 8 weeks after PDT was - 0.009 ± 0.032 (p = 0.127), whereas this was 0.0025 ± 0.037 (p = 0.723) between the visit before PDT and final visit. The patients in the PDT group had a CVI change of - 0.0025 ± 0.037 (p = 0.723) between the visit before PDT and first visit after PDT, and a mean CVI change of - 0.013 ± 0.038 (p = 0.080) between the visit before PDT and final visit. There was no significant correlation between CVI and BCVA at the measured time points, in both the HSML group (p = 0.885), and in the PDT group (p = 0.904). Moreover, no significant changes in CVI occurred in the unaffected eye at any time point.
PDT and HSML do not significantly affect CVI, and therefore a CVI change may not be primarily responsible for the treatment effect. The positive treatment effect of both interventions may rely on other mechanisms, such as an effect on choriocapillaris and/or retinal pigment epithelium function.
评估慢性中心性浆液性脉络膜视网膜病变(cCSC)的光动力疗法(PDT)和高密度亚阈值微脉冲激光(HSML)治疗是否会引起脉络膜血管指数(CVI)的变化,而这些变化可能是治疗效果的原因。
前瞻性纳入并分析了患有 cCSC 的患者。患者接受半剂量 PDT 或 HSML 治疗。在治疗前、治疗后 6-8 周和治疗后 7-8 个月获得受影响眼和未受影响眼的 CVI。
在基线时,29 只眼(29 名患者)同时纳入 PDT 组和 HSML 组。HSML 组在 PDT 前和治疗后 6-8 周之间的 CVI 变化平均值(±标准差)为-0.009±0.032(p=0.127),而在 PDT 前就诊和最后就诊之间为 0.0025±0.037(p=0.723)。PDT 组患者在 PDT 前就诊和 PDT 后第一次就诊之间的 CVI 变化为-0.0025±0.037(p=0.723),在 PDT 前就诊和最后就诊之间的平均 CVI 变化为-0.013±0.038(p=0.080)。在 HSML 组(p=0.885)和 PDT 组(p=0.904),在测量的时间点,CVI 与 BCVA 之间均无显著相关性。此外,在任何时间点,未受影响眼的 CVI 均无显著变化。
PDT 和 HSML 均不会显著影响 CVI,因此 CVI 变化可能不是治疗效果的主要原因。两种干预措施的积极治疗效果可能依赖于其他机制,例如对脉络膜毛细血管和/或视网膜色素上皮功能的影响。